StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
9438.T$566.00-0.70%
Fair $566.00+0.0%

9438.T

MTI Ltd.

Healthcare / Health Information ServicesTokyo

$566.00

-4.00 (-0.70%)

Fairly Valued+0.0%Fair Value $566.00Fund rank 32/100 · Data gapFallback financials|
SA 49/C
F-Score: 6/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 32% · confianza 24%

FCF escenarios

weak_data · normalized FCF $3.6B · quality 55.3/100

Data gap 32/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 39/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

49/100

C

Piotroski

6/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · 9438.TLocal privado en este navegador · MTI Ltd.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$31.4B

P/E

8.9x

↓

EV/EBITDA

2.5x

↓

ROE

18.5%

↑

Gross Margin

74.3%

↑

Debt/Equity

0.09

↓
52-Week Range$566
$561$973

TradingView lightweight chart

9438.T price, volumen y niveles de valoración

Último $566.00Periodo -96.3%
Fair value: $566.00

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+4.1%

FCF CAGR

—

FCF margin

14.4%

FCF / Net income

1.26x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $29.91B · net income $3.40B · FCF $4.30B

2022-FY → 2025-FY

Gross margin

74.3%+3.7% pts

Operating margin

9.8%+6.6% pts

Net margin

11.4%+14.9% pts

FCF margin

14.4%+27.9% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$29.91B$29.91B$27.67B$26.80B$26.48B
Net Income$3.40B$3.40B$2.36B$753.2M$-930.5M
EBITDA$6.02B$6.02B$5.17B$2.91B$1.44B
EPS61.5561.55—13.73-16.99
Gross Margin74.3%74.3%73.7%68.6%70.6%
Operating Margin9.8%9.8%8.7%1.1%3.3%
Net Margin11.4%11.4%8.5%2.8%-3.5%
Balance Sheet
Debt/Equity0.090.090.160.230.28
Current Ratio3.463.46———
Cash Flow
Free Cash Flow$4.30B$4.30B$2.74B$3.60B$-3.59B
Returns
ROE18.5%18.5%15.3%5.4%-6.6%
Valuation
P/E8.948.94—42.97—
EV/EBITDA2.522.5210.677.4913.64
P/B1.701.704.372.311.96
Growth & Yield
Revenue Growth8.1%8.1%3.2%1.2%—
EPS Growth———180.8%—
Dividend Yield3.5%3.5%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

-6.6%

fácil

EPS terminal req.

$50.22

Spread vs growth

14.7%

5Y implied EPS CAGR

-0.3%

fácil

EPS terminal req.

$60.77

Spread vs growth

8.4%

10Y implied EPS CAGR

4.7%

fácil

EPS terminal req.

$97.87

Spread vs growth

3.4%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -29.5%

Total return

-29.5%

Start / end P/E

n/dx → n/dx

EPS bridge

n/d → 61.55

Residual

-33.0%

EPS growthn/d
Multiple reratingn/d
Dividend+3.5%
Residual / FX / buybacks / cross-term-33.0%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.